Purpose: The delivery of high quality prostate cancer care is increasingly important for health systems, physicians and patients. Integrated delivery systems may have the greatest ability to deliver high quality, efficient care. We sought to understand the association between health care integration and quality of prostate cancer care. Materials and Methods: We used SEER-Medicare data to perform a retrospective cohort study of men older than age 65 with prostate cancer diagnosed between 2007 and 2011. We defined integration within a health care market based on the number of discharges from a top 100 integrated delivery system, and compared rates of adherence to well accepted prostate cancer quality measures in markets with no integration vs full integration (greater than 90% of discharges from an integrated system). Results: The average man treated in a fully integrated market was more likely to receive pretreatment counseling by a urologist and radiation oncologist (62.6% vs 60.3%, p¼0.03), avoid inappropriate imaging (72.2% avoided vs 60.6%, p <0.001), avoid treatment when life expectancy was less than 10 years (23.7% vs 17.3%, p <0.001) and avoid multiple hospitalizations in the last 30 days of life (50.2% vs 43.6%, p¼0.001) than when treated in markets with no integration. Additionally, patients treated in fully integrated markets were more likely to have complete adherence to all eligible quality measures (OR 1.38, 95% CI 1.27e1.50).
THE quality of prostate cancer care in the U.S. varies widely. 1 Uncertainty surrounding how best to treat men with localized prostate cancer is fueled by the considerable morbidity of treatments and the associated decrements in quality of life. Without question, public pressure to improve is mounting. The recent release of surgeon specific complication rates and the associated media attention only further amplify calls for accountability and meaningful improvement.
While surgeons can hone their surgical skills through collaborative quality improvement and other self-learning methods to work toward better outcomes, 2, 3 the best means to facilitate improvements in prostate cancer quality more broadly remain uncertain. Some believe that recent health reforms, which heighten the focus on stewardship of population health and accountable care, will inevitably drive quality improvement. 4 Enthusiasm for accountable care is based in part on successes in improving quality and efficiency by fully integrated delivery systems, such as Geisinger and Intermountain Healthcare. 5, 6 By definition, integrated delivery systems are organized, collaborative networks that link health care providers who are clinically and fiscally accountable for patient populations across the continuum of care. 7 Integrated delivery systems are often typified by a focus on fully coordinated, evidence-based health care, and have systems in place to manage and improve clinical outcomes. However, whether such integration is associated with higher quality prostate cancer care is uncertain.
Therefore, we performed a study to better understand the implications of health care integration for prostate cancer quality. We hypothesized that higher levels of integration would be associated with better quality. Our findings will help stakeholders anticipate the implications of ACOs, the progeny of integrated delivery systems, for specialist managed diseases such as prostate cancer.
MATERIALS AND METHODS
Using SEER-Medicare data we performed a retrospective cohort study of 72,411 men age 66 or older with newly diagnosed prostate cancer between 2007 and 2011, with followup data through December 31, 2013. All men were followed for at least 1 year after diagnosis. Our study was limited to men continuously enrolled in Medicare Parts A and B throughout the study period, and excluded men participating in Medicare managed care plans.
Measuring Market Level Health Care Integration
We examined quality at the market level rather than the hospital or facility level in an effort to understand patterns in quality of care for all patients with prostate cancer. Only surgical patients routinely receive care in a hospital setting, where attribution to a hospital that is part of an integrated delivery system is straightforward. For the nearly 80% of patients with newly diagnosed prostate cancer who receive care outside of a hospital setting, understanding the affiliation of the treating physician with an integrated system is a necessary step and these relationships are currently poorly defined. For these reasons we elected to examine the effects of integration at the market level.
We measured the level of integration within a health care market by determining the proportion of discharges coming from a top 100 integrated delivery system in each market. 8 The designation of a top 100 integrated delivery system was determined by Becker's Hospital Review based on rankings provided by a health care analytics firm, IMS HealthÔ, as well as an overall assessment of each health systems' financial, clinical and operations strength. Specifically, health systems are ranked based on their ability to operate as a unified organization among key domains, including integrated technology use, contractual capabilities, outpatient use, financial stability, services and access, hospital use and physicians.
Markets were defined by the boundaries of hospital referral regions as described in the Dartmouth Atlas of Health Care. 9 Each of the 306 HRRs in the U.S. consists of a collection of zip codes within which residing patients receive the bulk of their health care. Of these HRRs 105 are completely, or have a majority, located within SEER regions and, therefore, are included in this study to ensure capture of all health care services and clinical and pathological data. 10, 11 The proportion of discharges from a top 100 integrated delivery system was measured at the level of the HRR. The corresponding proportions of market level integration were assigned to the patients of the cohort based on their HRR and served as the exposure. In an effort to overcome heterogeneity of integration at the hospital level within HRRs, we compared quality at the ends of the spectrum (ie no integration vs fully integrated) to ensure that the presence of integration is uniform for patients within the HRRs examined. Fully integrated markets were defined as those HRRs with at least 90% of discharges from a top 100 integrated delivery system.
Outcomes
Measures to assess prostate cancer quality have been developed by researchers at RAND Health, the American Urological Association and the PCPI (see Appendix). 12 Subsequent studies have confirmed the feasibility of applying these indicators to evaluate quality 1,13e16 and the NQF has endorsed several of them for performance measurement. Each quality measure was assessed at the patient level. The numerator was the count of eligible men whose care adhered to the performance measure and the denominator was the number of men for whom the measure applied. For example, for the avoidance of imaging in low risk patients measure, the numerator would be the count of patients with low D'Amico risk prostate cancer (ie Gleason score of 6 or less and clinical stage T2a or less, not accounting for prostate specific antigen 17 ) who did not undergo pretreatment imaging. The denominator would be the count of all men with low risk prostate cancer.
Integrated delivery systems are more likely to adopt electronic health information systems with decision support and have access to patient centered care management programs. 18 Thus, the extent to which these quality measures are sensitive to health care integration almost certainly varies, as some (eg adherence to clinical guidelines on imaging use) are more reliant on organizational infrastructure and systems in place to guide clinical practice while others (eg use of adjuvant radiation in men with high risk pathology) are more influenced by the preferences of the physician and/or patient. Additionally, to the degree that primary care physicians are most often the orchestrators of integrated, patient centered care, we hypothesized that quality measures that involve primary care physicians are likely hypersensitive to health system integration. Based on the literature surrounding integrated delivery systems and quality, we selected a set of measures a priori that we believed to be hypersensitive to integration (see Appendix).
Analysis
We compared patient characteristics and regional characteristics from the Area Resource File (urban/rural status, Medicare Advantage penetration, and number of urologists, radiation oncologists and hospital beds per 100,000 population) for HRRs with no integration vs those with full integration using chi-square tests.
Next we constructed a series of multivariable logistic regression analyses to assess the association between the integration of health care markets and adherence to individual quality measures, adjusting for patient and regional characteristics. The models yielded predicted probabilities of compliance for HRRs with no integration vs full integration for the average patient (ie white, 70 to 74 years old, low risk [Gleason 6 and clinical stage T2a or less], no comorbidities, middle socioeconomic tercile, largest population tercile, intermediate number of urologists, radiation oncologists and hospital beds, and intermediate Medicare Advantage penetration). Using the same statistical approach we then fit an all or nothing model in which compliance required adherence to all quality measures for which the patient was eligible. As before, we compared the effect of no integration vs full integration.
To assess whether market integration had a particularly strong effect on what we hypothesized were the most sensitive of the quality measures (hypersensitive), we constructed a logistic model at the measure level (as opposed to the patient level), using generalized estimating equations to account for multiple measures per patient. Finally, an interaction term, formed by multiplying integration (continuous) and hypersensitivity (dichotomous), was added to the model.
All analyses were performed using SASÒ version 9.4. The probability of a 2-tailed type 1 error was set at 0.05. The study protocol was judged to be exempt by the institutional review board of the University of Michigan.
RESULTS
A total of 72,411 patients met the study inclusion criteria. Patient and market characteristics were contrasted according to the degree of market level integration, where 19,848 patients received care in 37 markets with no integration and 1,237 patients receive care in 1 of 3 fully integrated markets (supplementary table 1, http://jurology.com/). While similar in terms of age and D'Amico risk, patients treated in fully integrated markets were more often white (91.7% vs 80.5%, p <0.001) and without comorbidities (65.4% vs 60.9%, p¼0.01). Fully integrated markets were more likely to be located in metropolitan areas with a population greater than 1 million (74.1% vs 43.6%, p <0.001). They also had the highest per capita concentration of urologists and hospital beds. During the study interval our cohort had a 1.7% prostate cancer specific mortality rate and 15.7% all cause mortality rate.
As illustrated in the figure the average patient with prostate cancer receiving treatment in a fully integrated market was more likely to receive pretreatment counseling (62.6% vs 60.3%, p¼0.03) and avoid inappropriate imaging (72.2% avoided vs 60.6%, p <0.001) during the pretreatment period than if he were treated in a market with no integration. Men with prostate cancer treated in fully integrated markets were more likely to avoid treatment when noncancer life expectancy was less than 10 years (23.7% avoided vs 17.3%, p <0.001). However, they were slightly less likely to be treated by a high volume provider (73.3% vs 78.7%, p <0.001). In the posttreatment phase fully integrated markets performed better at avoiding multiple hospitalizations (more than 1) in the last 30 days of life (50.2% avoided vs 43.6%, p¼0.001).
Patients treated in fully integrated markets were more likely to receive ideal care (ie adherence to all eligible quality measures) than patients treated in markets with no integration (16.5% vs 12.5%, OR 1.38, 95% CI 1.27e1.50, supplementary table 2, http://jurology.com/).
Despite significantly improved odds of compliance with measures that we deemed hypersensitive (OR 0.70, 95% CI 0.69e0.71), we found no significant interaction between the degree of integration within the market and hypersensitive measures (interaction term p¼0.47). In other words, while adherence to hypersensitive measures is better than nonhypersensitive measures, this is true across health care markets and not significantly better in more integrated markets.
DISCUSSION
Health system integration is associated with improved adherence to a number of prostate cancer quality measures. Specifically, patients treated in fully integrated markets are more likely to receive pretreatment counseling by a radiation oncologist and a urologist, avoid unnecessary imaging for low risk prostate cancer, avoid treatment when life expectancy is less than 10 years and avoid multiple hospital admissions at the end of life. In addition to individual quality measures, patients treated in fully integrated markets had a 38% higher odds of receiving ideal care or having complete adherence to all eligible quality measures.
The delivery of high quality prostate cancer care has become increasingly important for health systems, physicians and patients. As the number of quality measures grows and the financial risk associated with meeting them increases, integrated delivery systems, and by extension ACOs, may be better positioned to deliver high quality, efficient care. Improved quality of care has been noted in integrated delivery systems and ACOs. 19, 20 Our findings add to this growing body of literature supporting increased health system integration as a means of improving quality of care.
However, our study has several limitations. It showed that integration is associated with improved adherence to certain prostate cancer quality measures, but not all measures show this relationship. Additionally, significant gaps in quality remain as evidenced by the overall low delivery of ideal care. Together these data suggest that while integration facilitates the delivery of high quality care, integration alone is not sufficient to maximize quality of care. Improved patient and physician education, uniform guidelines across specialties and multidisciplinary clinics may be other means of increasing quality care. Further financial incentives applied through recent policies focused on value and quality will likely act as additional levers to promote high quality care. In addition, much of prostate cancer care occurs outside the hospital setting and providers administering outpatient prostate cancer care may have little or no relationship with the dominant integrated system in the market. However, we elected to assign integration at the market level and examine outcomes at the extremes of integration (none vs fully integrated) in an effort to minimize the impact of this limitation. Finally, it is conceivable that integration may be a surrogate measure for some other characteristic of these markets that facilitates higher quality care. For example, the improvements we observed for integrated systems may be mediated by factors such as the incorporation of multidisciplinary clinics, a strong emphasis on shared decision making, the presence of patient care navigators or the robust use of electronic health records. While we hypothesized that integration represented a composite of these health system attributes, it is possible that one of these attributes or an unmeasured factor is driving the differences in quality that we observed.
These limitations notwithstanding, our findings have important implications for policymakers, health system leadership and patients. For policymakers, evidence that health system integration is associated with improved adherence to quality measures supports the development and Adjusted adherence to quality measures before, during and after treatment for average patient according to market level integration. Asterisk indicates p <0.05. ADT, androgen deprivation therapy. GI, gastrointestinal. GU, genitourinary.
dissemination of initiatives, such as ACOs, that aim to further encourage deeply integrated networks. ACOs have expanded rapidly with an estimated 23.5 million patients covered in a commercial, Medicaid or Medicare ACO in 2015. 21, 22 As increasing financial bonuses or penalties are tied to quality, health system leadership and physicians may find that increased integration helps support the delivery of high quality care in general as well as for specific conditions such as prostate cancer. Patients treated in integrated delivery systems will inevitably benefit from the improved adherence to quality measures as well as the more coordinated, efficient care provided in these settings. Despite these benefits, policy makers will also be cognizant of the unintended consequences of consolidation, which may drive higher spending by increasing an organization's bargaining power and reducing competition. 23 For practicing urologists our findings suggest that participation in an integrated delivery system may help facilitate the delivery of high quality care. Importantly, the MACRA (Medicare Access and CHIP Reauthorization Act of 2015) changes how physicians are reimbursed for services provided to Medicare beneficiaries by tying payments to quality. 24 Integrated delivery systems and ACOs will likely continue to grow under MACRA and urologists may have an opportunity to formally participate in these programs as an alternative to individual physician performance measurement. A greater understanding of the factors that influence the delivery of quality care will become increasingly relevant for urologists in this new payment environment.
CONCLUSIONS
Moving forward, policies that encourage health system integration may have downstream effects of facilitating the delivery of high quality care. Ultimately studies that explore the financial resources needed to build integrated networks and the costs associated with delivering high quality care will inform how wide dissemination of this model can realistically occur.
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